Real-world reductions in migraine and headache days after initiating fremanezumab for US patients with migraine and prior use of another monoclonal antibody targeting the CGRP pathway

被引：0

作者：

Driessen, M. T. ^{[1
]}

Patterson-Lomba, O. ^{[2
]}

Mu, F. ^{[2
]}

Thompson, S. F. ^{[3
]}

Seminerio, M. J. ^{[4
]}

Carr, K. ^{[4
]}

Sun, R. ^{[2
]}

Totev, T. ^{[2
]}

Yim, E. ^{[2
]}

Ayyagari, R. ^{[5
]}

Cohen, J. M. ^{[4
]}

机构：

[1] Teva Pharmaceut, Amsterdam, Netherlands

[2] Anal Grp, Boston, MA USA

[3] Teva Branded Pharmaceut Prod R&D Inc, Parsippany, NJ USA

[4] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA

[5] Anal Grp Inc, Boston, MA USA

来源：

HEADACHE | 2021年 / 61卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P-165

引用

页码：141 / 141

页数：1

共 50 条

[1] REDUCTIONS IN MIGRAINE AND HEADACHE DAYS AFTER INITIATING FREMANEZUMAB FOR PATIENTS WITH MIGRAINE AND PRIOR USE OF ANOTHER MONOCLONAL ANTIBODY TARGETING THE CGRP PATHWAY IN A US REAL-WORLD SETTING
Driessen, M.
Patterson-Lomba, O.
Mu, F.
Thompson, S.
Seminerio, M.
Carr, K.
Sun, R.
Totev, T.
Yim, E.
Ayyagari, R.
Cohen, J.
[J]. VALUE IN HEALTH, 2022, 25 (01) : S23 - S23
[2] Real-world Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab in the US
Cohen, Joshua M.
Thompson, Stephen
Patterson-Lomba, Oscar
Driessen, Maurice
Seminerio, Michael
Carr, Karen
Mu, Fan
[J]. NEUROLOGY, 2021, 96 (15)
[3] Real-world Reductions in Migraine and Headache Days for Patients With Migraine Initiating Fremanezumab in Germany
Heinze, A.
Totev, T.
Krasenbaum, L.
Terasawa, E.
Akcicek, H.
Hipp, J.
Sun, R.
Yim, E.
Driessen, M.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 419 - 419
[4] REDUCTIONS IN MIGRAINE AND HEADACHE DAYS WITH QUARTERLY AND MONTHLY FREMANEZUMAB IN ADULT PATIENTS WITH MIGRAINE IN A US REAL-WORLD SETTING
Cohen, J.
Thompson, S.
Ayyagari, R.
Driessen, M.
Seminerio, M.
Carr, K.
Yim, E.
[J]. VALUE IN HEALTH, 2022, 25 (01) : S36 - S36
[5] US Real-world Effectiveness of Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in Adult Patients With Migraine
Cohen, Joshua M.
Thompson, Stephen
Ayyagari, Rajeev
Driessen, Maurice
Seminerio, Michael
Carr, Karen
Yim, Erica
[J]. NEUROLOGY, 2021, 96 (15)
[6] Real-world data on reductions in migraine and headache days with fremanezumab treatment for US patients with chronic and episodic migraine: Results from a physician chart review study
Cohen, J. M.
Thompson, S. F.
Patterson-Lomba, O.
Driessen, M. T.
Seminerio, M. J.
Carr, K.
Mu, F.
[J]. HEADACHE, 2021, 61 : 70 - 71
[7] REAL-WORLD EFFECTIVENESS OF FREMANEZUMAB TREATMENT FOR REDUCING MONTHLY MIGRAINE AND HEADACHE DAYS IN US PATIENTS HAVING DIFFERENT NUMBERS OF PRIOR MIGRAINE PREVENTIVE TREATMENT FAILURES
Cohen, J.
Thompson, S.
Sun, R.
Driessen, M.
Seminerio, M.
Carr, K.
Mu, F.
[J]. VALUE IN HEALTH, 2022, 25 (01) : S30 - S30
[8] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
Andreas Straube
Gregor Broessner
Charly Gaul
Xenia Hamann
Joachim Hipp
Torsten Kraya
Lars Neeb
[J]. The Journal of Headache and Pain, 24
[9] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
Straube, Andreas
Broessner, Gregor
Gaul, Charly
Hamann, Xenia
Hipp, Joachim
Kraya, Torsten
Neeb, Lars
[J]. JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
[10] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
Maurice T. Driessen
Joshua M. Cohen
Stephen F. Thompson
Oscar Patterson-Lomba
Michael J. Seminerio
Karen Carr
Todor I. Totev
Rochelle Sun
Erica Yim
Fan Mu
Rajeev Ayyagari
[J]. The Journal of Headache and Pain, 2022, 23

← 1 2 3 4 5 →